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Background: Circulating endothelial cells (CECs) have been studied as a biomarker for 
tumor progression and monitoring therapeutic effects. The CellSearch system is a semi-
automated system that allows standardized analysis of CECs. This study assessed the 
clinical implications of CECs determined by the CellSearch system in breast cancer patients.  
Methods: Seventy-six consecutive breast cancer patients (53 operable and 23 metastatic or 
recurrent) were enrolled for the study. Thirty-five patients with operable breast cancer 
received preoperative chemotherapy with a regimen based on anthracycline and/or taxane. 








 cells in the system. CD34 expression 
was examined using the additional channel in the system.  
Results: A majority (4539 of 5183 cells, 88%) of CECs from patients with operable breast 
cancer were CD34-positive. Triple-negative cancers showed higher baseline CEC and 
CD34
+
CEC counts than the other types (P = 0.0387 and 0.0377, respectively). Low 
baseline CEC and CD34
+
CEC counts, and a low CD34 positive rate were associated with 
pathological complete response (pCR) of preoperative chemotherapy in patients with 
primary breast cancer (P = 0.046, 0.027 and 0.01, respectively). In multivariate analyses, 
the CD34 positive rate was significant for pCR (P = 0.021). During preoperative 
chemotherapy, CEC and CD34
+
CEC counts before each cycle of chemotherapy increased 
with taxane-based regimens (P = 0.0018 and 0.0008, respectively) but not with 
anthracycline-based regimens.  
Conclusions: Baseline CEC, in particular CD34
+
CEC, counts and the CD34 positive rate 
might be useful for the prediction of treatment response of preoperative chemotherapy in 









Circulating endothelial cells (CECs) and their progenitors, endothelial progenitor 
cells (EPCs), are being studied with increasing interest in oncology, particularly in relation 
to tumor angiogenesis. Recent studies have demonstrated elevated CEC count in patients 
with malignant diseases compared with healthy controls (1-7). Several pioneering studies 
have demonstrated that CEC elevations are associated with tumor stage, tumor 
characteristics and prognosis (4, 8-10). It has been experimentally demonstrated that 
chemotherapy causes a rapid induction of EPCs into the systemic circulation of mice, 
irrespective of the presence of tumor (11). EPC mobilization may support tumor cell 
survival even during anticancer chemotherapy.  
CECs and EPCs are currently determined by several different assay systems 
including the flow cytometry and immunomagnetic detection system using endothelial cell 
markers including CD31, CD34, and CD146, and progenitor cell markers including 
CD133(12). However, the markers and criteria that are used differ among studies (13, 14). 
The flow cytometry analysis has some limitations including standardization between 
different laboratories and difficulties in fresh blood shipping. Recently, a semi-automated 
system for the detection of CECs was developed. The CellSearch system (Veridex LLC, 
Raritan, NJ) is mostly automated but enables researchers to detect endothelial cells visually 
using the immunofluorescence system. This system allows standardized analyses in 
different laboratories and shipment of blood samples in special tubes containing 
preservatives. 
In this study, we used the CellSearch system to examine baseline CEC count and 
CEC alterations during systemic chemotherapy in association with clinicopathological 
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PATIENTS AND METHODS 
Patients 
We enrolled 76 consecutive patients with histologically confirmed breast cancer 
who were treated at Kyoto University Hospital between 2007 and 2009, comprising 53 
patients with operable breast cancer and 23 patients with metastatic or recurrent breast 
cancer.  Other inclusion criteria were age 20–70 years, performance status (ECOG) <3, and 
estimated survival time >3 months. Blood samples were drawn before the initiation of any 
treatment in the operable breast cancer group and before the initiation of treatment for the 
metastatic or recurrent breast cancer in the metastatic or recurrent breast cancer group. 
Thirty-five patients with operable breast cancer received preoperative chemotherapy with a 
regimen based on anthracycline, taxane or a combination of both.  The anthracycline-based 
regimen comprises four cycles of FEC (5-FU 500 mg/m
2










) tri-weekly. The taxane-based regimen comprised four 
cycles of docetaxel alone (75 mg/m
2





) tri-weekly. The combination regimen comprises four cycles 
of an anthracycline-based regimen tri-weekly and four cycles of a taxane-based regimen tri-
weekly. Trastuzumab was not administered preoperatively but after surgery to patients with 
HER2-positive tumors. We analyzed alterations in CEC count during treatment in 17 
patients who received preoperative chemotherapy by collecting blood samples before each 
cycle of chemotherapy and 24 hours after administration of chemotherapy. For combination 
regimen, blood samples were drawn during four cycles of the first regimen. Clinical 
response to chemotherapy was assessed according to the Response Evaluation Criteria in 
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Solid Tumors (RECIST). The study protocol was approved by the Ethics Committee of 
Kyoto University, and written informed consent was obtained from all patients. 
 
Evaluation of CECs by the CellSearch system 
Blood samples were drawn into CellSave tubes (Veridex, LLC, NJ) containing a cell 
preservative. Samples were maintained at room temperature and processed within 24 hours 
of collection. All evaluations were performed without prior knowledge of the clinical status 
of the patient. The CellSearch system, used for endothelial cell detection, consists of 
CellSave tubes, CellTracks AutoPrep, a fully automated sample preparation system, the 
Endothelial Cell Reagent Kit, and the CellSpotter Analyzer II, a semi-automated 
fluorescence microscope. 
In brief, 4 ml blood was mixed with 10 ml buffer, centrifuged at 800 ×g for 10 min, 
and placed in the sample preparation system. The instrument aspirated the plasma/buffer 
layer, and antiCD146 ferrofluids were added. After incubation and subsequent magnetic 
separation, unbound cells and the remaining plasma were aspirated. The enriched cells were 
fluorescently labeled with the nuclear stain 4,6-diamidino-2-phenylindole (DAPI). Staining 
reagents (<0.0006% mouse monoclonal antibodies specific to CD105 conjugated to 
phycoerythrin; <0.0013% mouse antiCD45 monoclonal antibodies conjugated to 
allophycocyanin in phosphate-buffered saline containing 0.5% BSA and 0.1% sodium 
azide) together with antiCD34 antibody conjugated to FITC (clone AC136, Miltenyi, 
Biotech GmbH, Germany) were added in conjunction with a permeabilization buffer to 
label the cells fluorescently. After incubation, magnetic separation was repeated to remove 
the excess staining reagent. After the final processing step, the cells were re-suspended in 
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300 µL of buffer and transferred to a chamber placed between two magnets that orient the 
immunomagnetically labeled cells in a monolayer for analyses. The cells were then 
examined with a four-color semi-automated fluorescent microscope, the CellSpotter 
Analyzer II. A gray-scale charge-coupled device camera was used to scan the entire 
chamber surface, and each captured frame was then evaluated for potential CEC candidates 








 cells.  
CECs were stained with an additional antibody against CD34 and its expression was 
evaluated using an extra channel in the system.  
 
Pathological analyses 
Tumor biopsy specimens before preoperative chemotherapy were examined 
pathologically for tumor grade according to the Scarff–Bloom–Richardson grading system. 
Tumor specimens were also examined for estrogen receptor (ER), progesterone receptor 
(PgR), and human epidermal growth factor receptor type 2 (HER2). The antibodies for ER, 
PgR, and HER2 were ER(SP1), PGR(1E2), and HER2(4B5), respectively (all from Roche 
Diagnostics, Tokyo, Japan). ER and PgR statuses were defined as positive for tumors 
having 10% or more positive tumor cells. HER2 positivity was determined by a strong 
expression (3+) of HER2 by the HercepTest or by an HER2:CEP17 ratio >2.2 by 
fluorescence in situ hybridization (FISH). Triple negative was defined as ER negative, PgR 
negative, and HER2 negative tumors. 
The pathological response was assessed after surgery following preoperative 
chemotherapy. A pathological complete response (pCR) was defined as no residual invasive 
tumor cells in mammary glands and lymph nodes. 
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The MIB1/Ki67 labeling index was calculated by counting positively stained tumor 
cells per 1000 tumor cells in the hot spots. Tumors having an MIB1/Ki67 index >20% were 
categorized as rapidly proliferative (positive), and those having an index <20% were 
defined as slowly proliferative (negative). 
 
Statistical analyses 
Correlation analyses were performed to assess the associations between baseline 
CEC counts and tumor size, nodal status, grade, stage, ER, PgR and HER2 statuses, tumor 
phenotype, and tumor response. Correlation analysis was performed using the Mann–
Whitney test for two independent samples and the Kruskal–Wallis test for more than two 
independent samples. Logistic regression analysis was used to identify parameters 
associated with pathological response. Changes in CEC and CEP numbers were analyzed 
using repeated measures ANOVA. Statistical analyses were performed using JMP (ver. 






Characteristics of CECs detected by the CellSearch system 
The expression of CD34, which is a commonly used marker for endothelial cells, was 
examined in CECs detected by the CellSearch system.  As shown in Figure 1, 88% (4539 
of 5183 cells) of CECs from patients with operable breast cancer before treatment were 
CD34 positive. 
 
Patient characteristics and correlations with clinicopathological parameters 
Table 1 shows the characteristics of the patients and their baseline CEC and 
CD34
+
CEC counts in relation to clinicopathological parameters. CD34 expression was not 
measured in two patients with operable breast cancer. CEC count was higher in metastatic 
or recurrent breast cancer patients than in patients with operable breast cancer (P = 0.0275). 
Among patients with operable breast cancer, those with triple-negative cancers had 
significantly higher CEC and CD34
+
CEC counts than those with other types of cancer (P = 
0.0387 and 0.0377, respectively). Similarly, patients with PR-negative cancers showed 
higher CEC and CD34
+
CEC counts than those with PR-positive cancers (P = 0.0413 and 
0.0437, respectively). In patients with metastatic or recurrent breast cancer, patients with 
lung, liver or bone metastasis showed higher CEC counts than those with lymph node or 




 CEC counts and responses to chemotherapy 
In 35 patients with operable breast cancer, CEC and CD34
+
CEC counts were 
examined according to pathological and clinical responses to preoperative chemotherapy. 
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The pCR group showed lower numbers of baseline CD34
+
CEC counts than the non-pCR 
group (P = 0.0416) (Figure 2). In addition, the pCR group showed a lower CD34-positive 
rate (CD34
+
CEC count/total CEC count) than the non-pCR group (P = 0.0356) (Figure 2). 
In the logistic regression analysis, CEC, CD34
+
CEC, and CD34-positive rates were 
significantly associated with pCR in univariate analyses (P = 0.046, 0.027, and 0.01, 
respectively) (Table 2). In multivariate analyses, the CD34-positive rate remained 
significant for pCR (P = 0.021) (Table 2). CEC counts, CD34
+
CEC counts, and CD34-
positive rate did not show any association with clinical responses (data not shown). 
 
Changes in CEC and CD34
+
CEC counts during systemic chemotherapy 
Alterations in CEC and CD34
+
CEC counts during the first four cycles of 
chemotherapy were analyzed in 17 patients with operable breast cancer who received 
preoperative chemotherapy as either a taxane-based or an anthracycline-based regimen. 
Patients who received taxane-based regimens showed increasing numbers of pretreatment 
CECs and CD34
+
CECs during the treatment cycles (P = 0.0018 and 0.0008, respectively) 
(Figure 3a) whereas those who received anthracycline-based regimens did not show such 
increases (P = 0.97 and 0.77, respectively) (Figure 3b). This indicates that changes in CEC 
and CD34
+
CEC counts depend on the type of chemotherapy. CEC and CD34
+
CEC counts 
showed a rapid increase 24 hours after each cycle of chemotherapy. Unlike anthracycline-
based regimens (Figure 3d), taxane-based regimens showed an incremental pattern in CEC 




At present, no standardized method is available to determine CEC and EPC counts, 
which makes reported data on CEC variable. The CellSearch system is a commercially 
available semi-automated system that enables standardized determination of CECs. A 
recent study reported that increases in CECs detected by the CellSearch system during 
antiangiogenic treatment were associated with improved outcome in metastatic breast 
cancer patients treated with bevacizumab and standard chemotherapy (15). However, CEC 
count by the CellSearch system is yet to be examined in patients with operable breast 
cancer. Thus, we examined clinical utility of CEC count by this system in patients with 
operable breast cancer, in particular during preoperative systemic chemotherapy. 
Our results showed that patients with triple-negative tumors had higher CEC and 
CD34
+
CEC counts compared with those who had other types of breast cancer. Intratumoral 
expression levels of vascular endothelial growth factor (VEGF)-A, stromal-derived growth 
factor (SDF)-1α and granulocyte colony-stimulating factor (G-CSF), all of which are 
known to mobilize EPCs (16, 17), are reported to be higher in basal-like tumors, which are 
a major subtype of triple-negative breast cancers (18). A cDNA microarray study with a 
series of 138 tumors (80 luminal A, which is an ER-positive subtype, and 58 basal-like) 
showed that basal-like tumors overexpressed genes associated with angiogenesis, such as 
VEGF genes compared with luminal-type tumors. In contrast, genes associated with 
antiangiogenesis, such as thrombospondin, type I, domain containing 1 (THSD1) and 
THSD4, were underexpressed in basal-like tumors (19). Patients with ER-positive tumors 
have been noted to have higher serum levels of endostatin, an intrinsic negative regulator of 
angiogenesis, compared to those with ER-negative tumors (20). Although the origin of 
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CECs determined by the CellSearch system is unclear, our results are in agreement with 
these reports and suggest that triple-negative breast cancers have more angiogenic 
properties than other types of breast cancer. 
Several recent studies have reported that elevated CEC count in cancer patients return 
to normal levels in response to systemic treatment (6, 7, 20-23). In the present study, the 
pCR group showed lower CD34
+
CEC count and a lower CD34-positive rate at baseline 
compared to the non-pCR group. In the logistic regression analysis, CD34
+
CEC count and 
the CD34-positive rate showed higher predictive power for pCR compared to CEC count. 
Furthermore, the CD34-positive rate remained significant for pCR in the multivariate 
analyses, suggesting that detection of CD34-positive population in CECs determined by the 
CellSearch system would increase their clinical utility. Further investigations are required 
to validate the clinical significance of CEC count, particularly by using larger prospective 
clinical studies that validate these findings in CD34-positive populations using the 
CellSearch system. 
In this study, as opposed to anthracycline-based regimens, taxane-based regimens 
caused increasing numbers of pretreatment CEC and CD34
+
CECcounts during 
chemotherapy. Although the origin of CECs is not completely understood, evidence 
suggests that CECs determined by the CellSearch system originated from damaged 
vasculature since CEC count increased after venesection and cannulation (24). Thus, our 
results suggest that different chemotherapeutic agents may cause vascular or tumor damage 
in different ways. Various chemotherapeutic agents have been suggested to induce different 
ways of mobilizing endothelial progenitor cells from bone marrow (11). Chemotherapeutic 
agents such as paclitaxel are suggested to upregulate angiogenic cytokines and chemokines 
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such as CXCL8 (IL8), probably through NF-κB activation (25-27). These cytokines and 
chemokines would also affect CEC count after chemotherapy.  We also showed a rapid 
increase of CEC and CD34
+
CEC count 24 hours after chemotherapy, which may be due to 
acute damage of tumor or normal vasculature by chemotherapy.  It was demonstrated that a 
rapid elevation of EPCs after chemotherapy resulted in the colonisation of tumours by the 
bone marrow-derived cells and the promotion of tumour angiogenesis, which would result 
in tumour recovery (11). Even in the absence of tumours, chemotherapy alone was shown 
to induce EPC mobilisation, although induced levels might differ depending on the type of 
chemotherapy. As the origin of CECs by the CellSearch system is not fully understood, 
further investigations are warranted to elucidate the mechanisms of chemotherapy-induced 
increases in CECs. Since the sample size is small and this is not a randomized trial, 
conducting a larger prospective randomized study is necessary to validate these results.  
In conclusion, we studied the clinical significance of CECs determined by the 
CellSearch system in patients with operable breast cancer during preoperative systemic 
chemotherapy. CEC count, CD34
+
CEC count, and CD34-positive rates at baseline were 
significantly associated with pCR and the CD34-positive rate remained significant in 
multivariate analyses, suggesting that the CD34-positive rate may predict therapeutic 
responses to preoperative chemotherapy. Our results indicate that alterations in CEC and 
CD34
+
CEC counts during systemic chemotherapy show different patterns depending on the 
type of chemotherapy. Because angiogenesis may possibly play an important role in cancer 
progression and therapeutic responses, conducting further studies is essential to clarify the 
origin of CECs determined by different assays and how angiogenic reactions are involved 
in therapeutic responses to anticancer treatment. The results of such studies will improve 
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the understanding of how antiangiogenic treatment should be combined with conventional 





This study was funded by a research grant from Japan’s Ministry of Health, Labor, 
and Welfare for a study on constructing an algorithm for multimodality therapy with 
biomarkers for primary breast cancer during the formulation of the decision-making 
process, led by Masakazu Toi (H18-3JIGAN-IPPAN-007, H19-3JIGAN-IPPAN-007). 
This work was supported in part by the Innovative Techno-Hub for Integrated 
Medical Bio-imaging Project of the Special Coordination Fund for Promoting Science and 









1. Brunner M, Thurnher D, Heiduschka G, Grasl M, Brostjan C, Erovic BM. Elevated 
levels of circulating endothelial progenitor cells in head and neck cancer patients. J Surg Oncol 
2008;98:545-50. 
2. Go RS, Jobe DA, Asp KE, Callister SM, Mathiason MA, Meyer LA, et al. Circulating 
endothelial cells in patients with chronic lymphocytic leukemia. Ann Hematol 2008;87:369-73. 
3. Greenfield JP, Jin DK, Young LM, Christos PJ, Abrey L, Rafii S, et al. Surrogate 
markers predict angiogenic potential and survival in patients with glioblastoma multiforme. 
Neurosurgery 2009;64:819-26. 
4. Ho JW, Pang RW, Lau C, Sun CK, Yu WC, Fan ST, et al. Significance of circulating 
endothelial progenitor cells in hepatocellular carcinoma. Hepatology 2006;44:836-43. 
5. Kawaishi M, Fujiwara Y, Fukui T, Kato T, Yamada K, Ohe Y, et al. Circulating 
endothelial cells in non-small cell lung cancer patients treated with carboplatin and paclitaxel. 
J Thorac Oncol 2009;4:208-13. 
6. Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, Bertolini F. Resting and 
activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 
2001;97:3658-61. 
7. Mancuso P, Colleoni M, Calleri A, Orlando L, Maisonneuve P, Pruneri G, et al. 
Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients 
receiving metronomic chemotherapy. Blood 2006;108:452-9. 
8. Beerepoot LV, Mehra N, Vermaat JS, Zonnenberg BA, Gebbink MF, Voest EE. Increased 
levels of viable circulating endothelial cells are an indicator of progressive disease in cancer 
patients. Ann Oncol 2004;15:139-45. 
9. DePrimo SE, Bello C. Surrogate biomarkers in evaluating response to anti-angiogenic 
agents: focus on sunitinib. Ann Oncol 2007;18 Suppl 10:x11-19. 
10. Dome B, Timar J, Dobos J, Meszaros L, Raso E, Paku S, et al. Identification and 
clinical significance of circulating endothelial progenitor cells in human non-small cell lung 
cancer. Cancer Res 2006;66:7341-7. 
11. Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH, Colleoni M, et al. 
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for 
antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008;14:263-73. 
12. Strijbos MH, Gratama JW, Kraan J, Lamers CH, den Bakker MA, Sleijfer S. 
Circulating endothelial cells in oncology: pitfalls and promises. Br J Cancer 2008;98:1731-5. 
13. Bertolini F, Shaked Y, Mancuso P, Kerbel RS. The multifaceted circulating endothelial 
19 
 
cell in cancer: towards marker and target identification. Nat Rev Cancer 2006;6:835-45. 
14. Yoder MC, Ingram DA. Endothelial progenitor cell: ongoing controversy for defining 
these cells and their role in neoangiogenesis in the murine system. Curr Opin Hematol 
2009;16:269-73. 
15. Bidard FC, Mathiot C, Degeorges A, Etienne-Grimaldi MC, Delva R, Pivot X, et al. 
Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast 
cancer patients treated first line with bevacizumab and chemotherapy. Ann Oncol 
2010;21:1765-71. 
16. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, et al. VEGF 
contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial 
progenitor cells. EMBO J 1999;18:3964-72. 
17. Jin DK, Shido K, Kopp HG, Petit I, Shmelkov SV, Young LM, et al. Cytokine-mediated 
deployment of SDF-1 induces revascularization through recruitment of CXCR4+ 
hemangiocytes. Nat Med 2006;12:557-67. 
18. Van den Eynden GG, Smid M, Van Laere SJ, Colpaert CG, Van der Auwera I, Bich TX, 
et al. Gene expression profiles associated with the presence of a fibrotic focus and the growth 
pattern in lymph node-negative breast cancer. Clin Cancer Res 2008;14:2944-52. 
19. Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Buttarelli M, Jacquemier J, et al. 
How different are luminal A and basal breast cancers? Int J Cancer 2009;124:1338-48. 
20. Furstenberger G, von Moos R, Lucas R, Thurlimann B, Senn HJ, Hamacher J, et al. 
Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of 
primary breast cancer. Br J Cancer 2006;94:524-31. 
21. Wierzbowska A, Robak T, Krawczynska A, Pluta A, Wrzesien-Kus A, Cebula B, et al. 
Kinetics and apoptotic profile of circulating endothelial cells as prognostic factors for induction 
treatment failure in newly diagnosed acute myeloid leukemia patients. Ann Hematol 
2008;87:97-106. 
22. Norden-Zfoni A, Desai J, Manola J, Beaudry P, Force J, Maki R, et al. Blood-based 
biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-
resistant gastrointestinal stromal tumor. Clin Cancer Res 2007;13:2643-50. 
23. Zhang H, Vakil V, Braunstein M, Smith EL, Maroney J, Chen L, et al. Circulating 
endothelial progenitor cells in multiple myeloma: implications and significance. Blood 
2005;105:3286-94. 
24. Strijbos MH, Verhoef C, Gratama JW, Sleijfer S. On the origin of (CD105+) circulating 
endothelial cells. Thromb Haemost 2009;102:347-51. 
20 
 
25. Camp ER, Li J, Minnich DJ, Brank A, Moldawer LL, MacKay SL, et al. Inducible 
nuclear factor-kappaB activation contributes to chemotherapy resistance in gastric cancer. J 
Am Coll Surg 2004;199:249-58. 
26. Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer 
drugs. Nat Rev Cancer 2005;5:297-309. 
27. Uslu R, Sanli UA, Dikmen Y, Karabulut B, Ozsaran A, Sezgin C, et al. Predictive value 
of serum interleukin-8 levels in ovarian cancer patients treated with paclitaxel-containing 






Figure 1: Distribution of CECs and CD34
+
 CECs in individual patients with operable 
breast cancer  
CEC and CD34
+
 CEC counts in individual patients with operable breast cancer are shown. 
Eighty-eight percent (4539 of 5183 cells) of CECs detected by the CellSearch system are 
CD34 positive CECs.  
 
Figure 2: CEC and CD34
+
 CEC counts and pathological responses  
The pCR group had lower baseline counts of CD34
+
 CECs than the non-pCR group (P = 
0.0416). CEC count showed a similar trend (P = 0.1087). The pCR group showed a lower 
CD34 positive rate than the non-pCR group (P = 0.0356). 
 
Figure 3: Changes in CEC and CD34
+
 CEC counts during preoperative chemotherapy 
CEC and CD34
+
 CEC counts before each cycle of chemotherapy were measured during 
preoperative chemotherapy. (a) Patients receiving a taxane-based regimen showed 
increasing numbers of CEC and CD34
+
 CEC during chemotherapy cycles (P = 0.0018 and 
0.0008, respectively). (b) Patients receiving an anthracycline-based regimen did not show 
increases in CEC and CD34
+
 CEC counts during preoperative chemotherapy (P = 0.97 and 
0.77, respectively). CEC and CD34
+
 CEC counts were repeatedly measured before and 24 h 
after each cycle of chemotherapy in 17 patients. (c) Patients receiving taxane-based 
chemotherapy showed an incremental pattern of CEC and CD34
+
 CEC counts during 
chemotherapy. (d) Patients receiving anthracycline-based chemotherapy did not show an 
incremental pattern of CEC and CD34
+
 CEC elevation after chemotherapy. 
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Table 1. Clinicopathological characteristics and baseline CEC and CD34
+
CEC counts 






Variables n Median n Median 
Cancer status       
 Operable breast cancer  53 55 0.0275 51 49 0.072 






         
Operable breast cancer        
 Menopausal status       
  Premenopausal 23 55 NS 23 49 NS 
  Postmenopausal 30 52  28 50  
 Tumor size (UICC)       
  T1 13 56 NS 12 54 NS 
  T2 29 49  29 37  
  T3 10 82  9 98  
  T4 1 55  1 51  
 Clinical nodal status       
  Negative 22 46 NS 21 37 NS 
  Positive 28 90  27 77  
 Histological grade       
  1 6 26 NS 6 22 NS 
  2 19 56  19 45  
  3 28 55  26 55  
 Estrogen Receptor (ER)       
  Negative 26 62 0.1445 24 66 0.0715 
  Positive 27 43  27 36  
 Progesterone Receptor (PgR)       
  Negative 34 62 0.0413 32 66 0.0437 
  Positive 19 28  19 24  
 HER2 status       
  Negative 41 56 NS 41 49 NS 




†       
  Triple negative 17 96 0.0387 17 91 0.0377 
  Non-triple negative 36 40  34 36  
 Ki-67 index       
  Negative 7 38 NS 7 36 NS 
    Positive 28 55   28 49   
         
Metastatic or recurrent breast cancer        
 Major metastatic site       
  Lymph node 5 26  0.037  5 25  0.102  
  Lung 6 227   6 148   
  Liver 7 156   4 102   
  Bone 4 163   3 146   
  Skin 1 40   1 40   
 Estrogen Receptor       
  Negative 12 90  0.065  12 71  0.124  
  Positive 11 172   11 152   
 Progesterone Receptor       
  Negative 13 104  0.217  13 70  0.285  
  Positive 9 156   9 140   
  unknown 1 271   1 163   
 HER2 status       
  Negative 17 122  0.834  17 102  0.972  
  Positive 6 135   6 81   
†
Triple negative: ER, PgR, and HER2 negative
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Table 2. Univariate and multivariate analysis for pCR (logistic regression analysis) 
(n = 35) 
Univariate analysis 
Parameters P value 
age 0.144 
Tumor size (T3 − T4 vs T1 − T2) 0.303 
N (positive vs negative) 0.350 
ER (positive vs negative) 0.207 
PgR (positive vs negative) 0.625 
HER2 (positive vs negative) 0.385 





CD34-positive rate 0.01 
Multivariate analysis  
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